Zelboraf shows survival gains in study of BRAF melanoma

02/28/2012 | Modern Medicine

Zelboraf can extend the lives of some melanoma patients by several months, according to a multicenter study involving 132 people with BRAF V600-mutant advanced melanoma. Researchers recorded an overall response rate of 53% to the drug, according to findings published in the New England Journal of Medicine.

View Full Article in:

Modern Medicine